Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-2-4
pubmed:abstractText
The PI3K/AKT/mTOR pathway has been shown to play an important role in cancer. Starting with compounds 1 and 2 (GDC-0941) as templates, (thienopyrimidin-2-yl)aminopyrimidines were discovered as potent inhibitors of PI3K or both PI3K and mTOR. Structural information derived from PI3K gamma-ligand cocrystal structures of 1 and 2 were used to design inhibitors that maintained potency for PI3K yet improved metabolic stability and oral bioavailability relative to 1. The addition of a single methyl group to the optimized 5 resulted in 21, which had significantly reduced potency for mTOR. The lead compounds 5 (GNE-493) and 21 (GNE-490) have good pharmacokinetic (PK) parameters, are highly selective, demonstrate knock down of pathway markers in vivo, and are efficacious in xenograft models where the PI3K pathway is deregulated. Both compounds were compared in a PI3K alpha mutated MCF7.1 xenograft model and were found to have equivalent efficacy when normalized for exposure.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Class Ib Phosphatidylinositol..., http://linkedlifedata.com/resource/pubmed/chemical/Intracellular Signaling Peptides..., http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes, http://linkedlifedata.com/resource/pubmed/chemical/Phosphatidylinositol 3-Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Pik3cg protein, mouse, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines, http://linkedlifedata.com/resource/pubmed/chemical/TOR Serine-Threonine Kinases, http://linkedlifedata.com/resource/pubmed/chemical/Thiophenes, http://linkedlifedata.com/resource/pubmed/chemical/mTOR protein, mouse
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1520-4804
pubmed:author
pubmed-author:BerryMeganM, pubmed-author:CastanedoGeorgetteG, pubmed-author:ChangZhigangZ, pubmed-author:ChuckowreeIrinaI, pubmed-author:DotsonJennaJ, pubmed-author:FolkesAdrianA, pubmed-author:FriedmanLoriL, pubmed-author:GoldsmithRichardR, pubmed-author:HeffronTimT, pubmed-author:LeeLeslieL, pubmed-author:LesnickJohnJ, pubmed-author:LewisCristinaC, pubmed-author:NonomiyaJimJ, pubmed-author:OliveroAlanA, pubmed-author:PangJodieJ, pubmed-author:PriorWei WeiWW, pubmed-author:SalphatiLaurentL, pubmed-author:SampathDeepakD, pubmed-author:SiderisSteveS, pubmed-author:SimonMathieuM, pubmed-author:SutherlinDaniel PDP, pubmed-author:TianQingpingQ, pubmed-author:TsuiVickieV, pubmed-author:WanNan ChiNC, pubmed-author:WangShumeiS, pubmed-author:WiesmannChristianC, pubmed-author:WongSusanS, pubmed-author:ZhuBing-YanBY
pubmed:issnType
Electronic
pubmed:day
11
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1086-97
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:20050669-Administration, Oral, pubmed-meshheading:20050669-Animals, pubmed-meshheading:20050669-Cell Proliferation, pubmed-meshheading:20050669-Class Ib Phosphatidylinositol 3-Kinase, pubmed-meshheading:20050669-Intracellular Signaling Peptides and Proteins, pubmed-meshheading:20050669-Isoenzymes, pubmed-meshheading:20050669-Mice, pubmed-meshheading:20050669-Mice, Nude, pubmed-meshheading:20050669-Phosphatidylinositol 3-Kinases, pubmed-meshheading:20050669-Protein Kinase Inhibitors, pubmed-meshheading:20050669-Protein-Serine-Threonine Kinases, pubmed-meshheading:20050669-Pyrimidines, pubmed-meshheading:20050669-Structure-Activity Relationship, pubmed-meshheading:20050669-TOR Serine-Threonine Kinases, pubmed-meshheading:20050669-Thiophenes, pubmed-meshheading:20050669-Xenograft Model Antitumor Assays
pubmed:year
2010
pubmed:articleTitle
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
pubmed:affiliation
Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA. sutherlin.dan@gene.com
pubmed:publicationType
Journal Article